RP 严重程度与硝苯地平:高质量的证据表明,相较安慰剂,经过 4-12 周的治疗后,硝苯地平可降低发作频率和严重程度。[39]Challenor VF, Waller DG, Hayward RA, et al. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon. Angiology. 1989;40:122-128.http://www.ncbi.nlm.nih.gov/pubmed/2644877?tool=bestpractice.com[40]Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160:1101-1108.http://archinte.jamanetwork.com/article.aspx?articleid=485288http://www.ncbi.nlm.nih.gov/pubmed/10789602?tool=bestpractice.com[41]Sarkozi J, Bookman AA, Mahon W, et al. Nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol. 1986;13:331-336.http://www.ncbi.nlm.nih.gov/pubmed/3723496?tool=bestpractice.com[42]Corbin DO, Wood DA, Macintyre CC, et al. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Eur Heart J. 1986;7:165-170.http://www.ncbi.nlm.nih.gov/pubmed/3516704?tool=bestpractice.com[43]Gjorup T, Kelbaek H, Hartling OJ, et al. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. Am Heart J. 1986;111:742-745.http://www.ncbi.nlm.nih.gov/pubmed/3513504?tool=bestpractice.com[44]Waller DG, Challenor VF, Francis DA, et al. Clinical and rheological effects of nifedipine in Raynaud's phenomenon. Br J Clin Pharmacol. 1986;22:449-454.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401145/http://www.ncbi.nlm.nih.gov/pubmed/3533127?tool=bestpractice.com[45]Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2012;(7):CD006687.http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006687.pub3/fullhttp://www.ncbi.nlm.nih.gov/pubmed/22786498?tool=bestpractice.com 它也可改善总体症状。
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度与硝苯地平:高质量的证据表明,相较安慰剂,经过 4-12 周的治疗后,硝苯地平可降低发作频率和严重程度。[39]Challenor VF, Waller DG, Hayward RA, et al. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon. Angiology. 1989;40:122-128.http://www.ncbi.nlm.nih.gov/pubmed/2644877?tool=bestpractice.com[40]Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160:1101-1108.http://archinte.jamanetwork.com/article.aspx?articleid=485288http://www.ncbi.nlm.nih.gov/pubmed/10789602?tool=bestpractice.com[41]Sarkozi J, Bookman AA, Mahon W, et al. Nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol. 1986;13:331-336.http://www.ncbi.nlm.nih.gov/pubmed/3723496?tool=bestpractice.com[42]Corbin DO, Wood DA, Macintyre CC, et al. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Eur Heart J. 1986;7:165-170.http://www.ncbi.nlm.nih.gov/pubmed/3516704?tool=bestpractice.com[43]Gjorup T, Kelbaek H, Hartling OJ, et al. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon. Am Heart J. 1986;111:742-745.http://www.ncbi.nlm.nih.gov/pubmed/3513504?tool=bestpractice.com[44]Waller DG, Challenor VF, Francis DA, et al. Clinical and rheological effects of nifedipine in Raynaud's phenomenon. Br J Clin Pharmacol. 1986;22:449-454.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401145/http://www.ncbi.nlm.nih.gov/pubmed/3533127?tool=bestpractice.com[45]Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2012;(7):CD006687.http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006687.pub3/fullhttp://www.ncbi.nlm.nih.gov/pubmed/22786498?tool=bestpractice.com 它也可改善总体症状。
RP 严重程度/发作频率:中等质量证据表明,外用硝酸酯类药物可降低原发性和继发性 RP 的发作频率和严重程度,并可改善肢端溃疡。口服、经皮或外用硝酸酯类药物可引起副作用如各类头痛,因而限制了该类药的使用。[34]Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol. 1995;34:636-641.http://www.ncbi.nlm.nih.gov/pubmed/7670782?tool=bestpractice.com[35]Franks AG Jr. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet. 1982;1:76-77.http://www.ncbi.nlm.nih.gov/pubmed/6119495?tool=bestpractice.com[36]Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60:870-877.http://onlinelibrary.wiley.com/doi/10.1002/art.24351/fullhttp://www.ncbi.nlm.nih.gov/pubmed/19248104?tool=bestpractice.com[37]Hummers LK, Dugowson CE, Dechow FJ, et al. A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Ann Rheum Dis. 2013;72:1962-1967.http://www.ncbi.nlm.nih.gov/pubmed/23268365?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:中等质量证据表明,外用硝酸酯类药物可降低原发性和继发性 RP 的发作频率和严重程度,并可改善肢端溃疡。口服、经皮或外用硝酸酯类药物可引起副作用如各类头痛,因而限制了该类药的使用。[34]Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol. 1995;34:636-641.http://www.ncbi.nlm.nih.gov/pubmed/7670782?tool=bestpractice.com[35]Franks AG Jr. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet. 1982;1:76-77.http://www.ncbi.nlm.nih.gov/pubmed/6119495?tool=bestpractice.com[36]Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60:870-877.http://onlinelibrary.wiley.com/doi/10.1002/art.24351/fullhttp://www.ncbi.nlm.nih.gov/pubmed/19248104?tool=bestpractice.com[37]Hummers LK, Dugowson CE, Dechow FJ, et al. A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Ann Rheum Dis. 2013;72:1962-1967.http://www.ncbi.nlm.nih.gov/pubmed/23268365?tool=bestpractice.com
RP 严重程度/发作频率与地尔硫䓬:中等质量证据表明,相较安慰剂,经过 8 周治疗,地尔硫䓬可显著降低发作次数(地尔硫䓬组发作次数从基线处平均降低了 22.9/月,安慰剂组降低了 4.6/月; P <0.01),以及发作持续时间(地尔硫䓬组从基线处平均减少了 444 分钟/月,安慰剂减少了 160 分钟/月;P <0.01)。方法缺陷包括缺乏意向治疗分析。[49]Rhedda A, McCans J, Willan AR, et al. A double blind controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. J Rheumatol. 1985;12:724-727.http://www.ncbi.nlm.nih.gov/pubmed/3903157?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率与地尔硫䓬:中等质量证据表明,相较安慰剂,经过 8 周治疗,地尔硫䓬可显著降低发作次数(地尔硫䓬组发作次数从基线处平均降低了 22.9/月,安慰剂组降低了 4.6/月; P <0.01),以及发作持续时间(地尔硫䓬组从基线处平均减少了 444 分钟/月,安慰剂减少了 160 分钟/月;P <0.01)。方法缺陷包括缺乏意向治疗分析。[49]Rhedda A, McCans J, Willan AR, et al. A double blind controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. J Rheumatol. 1985;12:724-727.http://www.ncbi.nlm.nih.gov/pubmed/3903157?tool=bestpractice.com
RP 严重程度/发作频率:中等质量证据提供了氯沙坦治疗 RP 的效果。该药物经批准可用于治疗 HTN,而且发现其治疗 RP 的作用良好且耐受性好。[50]Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999; 42:2646-2655.http://onlinelibrary.wiley.com/doi/10.1002/1529-0131%28199912%2942:12%3C2646::AID-ANR21%3E3.0.CO;2-T/pdfhttp://www.ncbi.nlm.nih.gov/pubmed/10616013?tool=bestpractice.com[51]Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother. 2006;40:1998-2002.http://www.ncbi.nlm.nih.gov/pubmed/17003081?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:中等质量证据提供了氯沙坦治疗 RP 的效果。该药物经批准可用于治疗 HTN,而且发现其治疗 RP 的作用良好且耐受性好。[50]Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999; 42:2646-2655.http://onlinelibrary.wiley.com/doi/10.1002/1529-0131%28199912%2942:12%3C2646::AID-ANR21%3E3.0.CO;2-T/pdfhttp://www.ncbi.nlm.nih.gov/pubmed/10616013?tool=bestpractice.com[51]Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother. 2006;40:1998-2002.http://www.ncbi.nlm.nih.gov/pubmed/17003081?tool=bestpractice.com
RP 严重程度/发作频率:中等质量证据提供了氟西汀的疗效。有 RP 患者应用氟西汀(一个被批准用于抑郁和一些焦虑障碍治疗的 SSRI)治疗的阳性试验数据。[52]Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40:1038-1043.http://rheumatology.oxfordjournals.org/content/40/9/1038.fullhttp://www.ncbi.nlm.nih.gov/pubmed/11561116?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:中等质量证据提供了氟西汀的疗效。有 RP 患者应用氟西汀(一个被批准用于抑郁和一些焦虑障碍治疗的 SSRI)治疗的阳性试验数据。[52]Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40:1038-1043.http://rheumatology.oxfordjournals.org/content/40/9/1038.fullhttp://www.ncbi.nlm.nih.gov/pubmed/11561116?tool=bestpractice.com
RP 严重程度/发作频率:中等质量证据提供了卡托普利的有效性,数据来源于一项采用卡托普利治疗原发性 RP 的阳性试验。[51]Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother. 2006;40:1998-2002.http://www.ncbi.nlm.nih.gov/pubmed/17003081?tool=bestpractice.com[54]Rustin MH, Almond NE, Beacham JA, et al. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol. 1987;117:751.http://www.ncbi.nlm.nih.gov/pubmed/3322358?tool=bestpractice.com 然而,一项 meta 分析发现,除钙通道阻滞剂外的血管扩张剂(包括依那普利、丁咯地尔、贝前列素、达唑氧苯和酮色林)对原发性 RP 的治疗并无效。[45]Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2012;(7):CD006687.http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006687.pub3/fullhttp://www.ncbi.nlm.nih.gov/pubmed/22786498?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:中等质量证据提供了卡托普利的有效性,数据来源于一项采用卡托普利治疗原发性 RP 的阳性试验。[51]Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother. 2006;40:1998-2002.http://www.ncbi.nlm.nih.gov/pubmed/17003081?tool=bestpractice.com[54]Rustin MH, Almond NE, Beacham JA, et al. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol. 1987;117:751.http://www.ncbi.nlm.nih.gov/pubmed/3322358?tool=bestpractice.com 然而,一项 meta 分析发现,除钙通道阻滞剂外的血管扩张剂(包括依那普利、丁咯地尔、贝前列素、达唑氧苯和酮色林)对原发性 RP 的治疗并无效。[45]Stewart M, Morling JR. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2012;(7):CD006687.http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006687.pub3/fullhttp://www.ncbi.nlm.nih.gov/pubmed/22786498?tool=bestpractice.com
肢端溃疡愈合:中等质量证据表明,西地那非可促进肢端溃疡愈合。两项针对严重 RP 的实验指出,相较安慰剂,西地那非对于治愈肢端溃疡有更高的可能性;一项试验采用的他达拉非。[59]Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010;49:2420-2428.http://www.ncbi.nlm.nih.gov/pubmed/20837499?tool=bestpractice.com然而,尚缺乏 PDE-5 研究的初期结果。[58]Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980-2985.http://circ.ahajournals.org/content/112/19/2980.fullhttp://www.ncbi.nlm.nih.gov/pubmed/16275885?tool=bestpractice.com[59]Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010;49:2420-2428.http://www.ncbi.nlm.nih.gov/pubmed/20837499?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
肢端溃疡愈合:中等质量证据表明,西地那非可促进肢端溃疡愈合。两项针对严重 RP 的实验指出,相较安慰剂,西地那非对于治愈肢端溃疡有更高的可能性;一项试验采用的他达拉非。[59]Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010;49:2420-2428.http://www.ncbi.nlm.nih.gov/pubmed/20837499?tool=bestpractice.com然而,尚缺乏 PDE-5 研究的初期结果。[58]Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980-2985.http://circ.ahajournals.org/content/112/19/2980.fullhttp://www.ncbi.nlm.nih.gov/pubmed/16275885?tool=bestpractice.com[59]Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010;49:2420-2428.http://www.ncbi.nlm.nih.gov/pubmed/20837499?tool=bestpractice.com
保暖与 RP: 大多数临床医生建议避免接触寒冷以防止 RP 发作(若可能),但尚无试验评估其效果。[30]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002;7:328-335.http://www.altmedrev.com/publications/7/4/328.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
保暖与 RP: 大多数临床医生建议避免接触寒冷以防止 RP 发作(若可能),但尚无试验评估其效果。[30]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002;7:328-335.http://www.altmedrev.com/publications/7/4/328.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com
吸烟与 RP 进展风险:尚无证据表明吸烟与 RP 进展风险的关系,但它有临床意义。尚无有关 RP 戒烟的随机对照试验,但香烟烟雾中收缩血管的物质可能会恶化 RP。在吸烟者(尤其是老年人群)中,其动脉粥样硬化的混杂影响可能会对已经发生在 RP 中的正调节因素产生不利影响。
系统评价或者受试者>200名的随机对照临床试验(RCT)。
吸烟与 RP 进展风险:尚无证据表明吸烟与 RP 进展风险的关系,但它有临床意义。尚无有关 RP 戒烟的随机对照试验,但香烟烟雾中收缩血管的物质可能会恶化 RP。在吸烟者(尤其是老年人群)中,其动脉粥样硬化的混杂影响可能会对已经发生在 RP 中的正调节因素产生不利影响。
RP 严重程度/发作频率:质量差的证据表明,相较安慰剂,经过 8 周治疗后,尼卡地平可降低 RP 发作频率,但随机试验未发现发作的严重程度有显著差异。[46]French Cooperative Multicenter Group for Raynaud Phenomenon. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. Am Heart J. 1991;122:352-355.http://www.ncbi.nlm.nih.gov/pubmed/2053556?tool=bestpractice.com另一项试验发现,相较安慰剂,尼卡地平在发作频率、严重程度或持续时间上无显著差异。该试验还不足以检测临床结果上的重要差异。[47]Wollersheim H, Thien T. Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. J Cardiovasc Pharmacol. 1991;18:813-818.http://www.ncbi.nlm.nih.gov/pubmed/1725892?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:质量差的证据表明,相较安慰剂,经过 8 周治疗后,尼卡地平可降低 RP 发作频率,但随机试验未发现发作的严重程度有显著差异。[46]French Cooperative Multicenter Group for Raynaud Phenomenon. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. Am Heart J. 1991;122:352-355.http://www.ncbi.nlm.nih.gov/pubmed/2053556?tool=bestpractice.com另一项试验发现,相较安慰剂,尼卡地平在发作频率、严重程度或持续时间上无显著差异。该试验还不足以检测临床结果上的重要差异。[47]Wollersheim H, Thien T. Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon. J Cardiovasc Pharmacol. 1991;18:813-818.http://www.ncbi.nlm.nih.gov/pubmed/1725892?tool=bestpractice.com
RP 严重程度/发作频率与氨氯地平:质量差的证据表明,根据 7 周的基线分析氨氯地平可显著降低每周急性发作次数(基线 11.8 次发作/周至治疗后 8.6 次发作/周;P <0.001),且降低基线发作严重程度(基线 7.8 的不适评分降至治疗后 5.1)。然而,该试验方法存在明显缺陷。[48]La Civita L, Pitaro N, Rossi M, et al. Amlodipine in the treatment of Raynaud's phenomenon. A double-blind placebo-controlled crossover study. Clin Drug Invest. 1997;13:126-131.http://www.ncbi.nlm.nih.gov/pubmed/8508292?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率与氨氯地平:质量差的证据表明,根据 7 周的基线分析氨氯地平可显著降低每周急性发作次数(基线 11.8 次发作/周至治疗后 8.6 次发作/周;P <0.001),且降低基线发作严重程度(基线 7.8 的不适评分降至治疗后 5.1)。然而,该试验方法存在明显缺陷。[48]La Civita L, Pitaro N, Rossi M, et al. Amlodipine in the treatment of Raynaud's phenomenon. A double-blind placebo-controlled crossover study. Clin Drug Invest. 1997;13:126-131.http://www.ncbi.nlm.nih.gov/pubmed/8508292?tool=bestpractice.com
RP 严重程度/发作频率:质量差的证据表明,相较安慰剂,经过 6 周治疗后,哌唑嗪可降低 RP 发作次数,但该小型交叉试验发现发作的严重程度无显著差异。[53]Wollersheim H, Thien T, Fennis J, et al. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. Clin Pharmacol Ther. 1986;40:219-225.http://www.ncbi.nlm.nih.gov/pubmed/3731684?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:质量差的证据表明,相较安慰剂,经过 6 周治疗后,哌唑嗪可降低 RP 发作次数,但该小型交叉试验发现发作的严重程度无显著差异。[53]Wollersheim H, Thien T, Fennis J, et al. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. Clin Pharmacol Ther. 1986;40:219-225.http://www.ncbi.nlm.nih.gov/pubmed/3731684?tool=bestpractice.com
RP 严重程度/发作频率:质量差的证据表明,经过 2 个月的治疗,草酸萘呋胺可降低 RP 发作持续时间和强度,并可降低发作对日常活动的影响。但该药的证据有限。[56]Davinroy M, Mosnier M. Double-blind clinical evaluation of naftidrofuryl in Raynaud's phenomenon [in French]. Sem Hop Paris. 1993;69:1322-1326.
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:质量差的证据表明,经过 2 个月的治疗,草酸萘呋胺可降低 RP 发作持续时间和强度,并可降低发作对日常活动的影响。但该药的证据有限。[56]Davinroy M, Mosnier M. Double-blind clinical evaluation of naftidrofuryl in Raynaud's phenomenon [in French]. Sem Hop Paris. 1993;69:1322-1326.
RP 严重程度/发作频率:质量差的证据表明,在一项小型研究中 (n = 21),月见草油可降低 RP 的发作频率。[70]Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. J Thromb Haemost. 1985;54:490.http://www.ncbi.nlm.nih.gov/pubmed/4082084?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:质量差的证据表明,在一项小型研究中 (n = 21),月见草油可降低 RP 的发作频率。[70]Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. J Thromb Haemost. 1985;54:490.http://www.ncbi.nlm.nih.gov/pubmed/4082084?tool=bestpractice.com
ω-3 脂肪酸与 RP:质量差的证据提供了该治疗的疗效。显示鱼油可增加原发性及继发性 RP 患者肢端的收缩压,以及延长接触寒冷后症状发作的时间。[71]DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's: a double-blind, controlled, prospective study. Am J Med. 1989;68:158-164.http://www.ncbi.nlm.nih.gov/pubmed/2536517?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
ω-3 脂肪酸与 RP:质量差的证据提供了该治疗的疗效。显示鱼油可增加原发性及继发性 RP 患者肢端的收缩压,以及延长接触寒冷后症状发作的时间。[71]DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's: a double-blind, controlled, prospective study. Am J Med. 1989;68:158-164.http://www.ncbi.nlm.nih.gov/pubmed/2536517?tool=bestpractice.com
RP 严重程度/发作频率:质量差的证据表明,针对原发性 RP,使用银杏、 草药抗氧化剂可降低每周事件发生次数。[72]Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo controlled trial. Vasc Med. 2002;7:265-267.http://www.ncbi.nlm.nih.gov/pubmed/12710841?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:质量差的证据表明,针对原发性 RP,使用银杏、 草药抗氧化剂可降低每周事件发生次数。[72]Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo controlled trial. Vasc Med. 2002;7:265-267.http://www.ncbi.nlm.nih.gov/pubmed/12710841?tool=bestpractice.com
RP 严重程度/发作频率:质量差的证据提供了针灸的疗效。仅一项针对原发性 RP 的小型临床试验有阳性发现。[74]Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med. 1997;241:119.http://www.ncbi.nlm.nih.gov/pubmed/9077368?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:质量差的证据提供了针灸的疗效。仅一项针对原发性 RP 的小型临床试验有阳性发现。[74]Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med. 1997;241:119.http://www.ncbi.nlm.nih.gov/pubmed/9077368?tool=bestpractice.com
RP 严重程度/发作频率:质量差的证据提供了弱激光治疗的疗效。仅发现了一项针对弱激光用于原发性和继发性 RP 治疗的小型试验 (n = 47)。[75]Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud's phenomenon. Vasa. 2004;33:25-29.http://www.ncbi.nlm.nih.gov/pubmed/11771213?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:质量差的证据提供了弱激光治疗的疗效。仅发现了一项针对弱激光用于原发性和继发性 RP 治疗的小型试验 (n = 47)。[75]Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud's phenomenon. Vasa. 2004;33:25-29.http://www.ncbi.nlm.nih.gov/pubmed/11771213?tool=bestpractice.com
RP 严重程度/发作频率:质量差的证据提供了陶瓷浸渍手套的使用。[30]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002;7:328-335.http://www.altmedrev.com/publications/7/4/328.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
RP 严重程度/发作频率:质量差的证据提供了陶瓷浸渍手套的使用。[30]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002;7:328-335.http://www.altmedrev.com/publications/7/4/328.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com
继发于 RP 的硬皮病:质量差的证据支持此发现。一项涉及 10 项前瞻性观察性研究的系统性评价(总计 639 例原发性 RP 受试者)发现,13% 后来发展成硬皮病。[88]Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med. 1998;158:595-600.http://archinte.jamanetwork.com/article.aspx?articleid=191635http://www.ncbi.nlm.nih.gov/pubmed/9521223?tool=bestpractice.com
系统评价或者受试者>200名的随机对照临床试验(RCT)。
继发于 RP 的硬皮病:质量差的证据支持此发现。一项涉及 10 项前瞻性观察性研究的系统性评价(总计 639 例原发性 RP 受试者)发现,13% 后来发展成硬皮病。[88]Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med. 1998;158:595-600.http://archinte.jamanetwork.com/article.aspx?articleid=191635http://www.ncbi.nlm.nih.gov/pubmed/9521223?tool=bestpractice.com